Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19
Plus mRNA Vaccines To Carry Myocarditis Warning
Executive Summary
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.
You may also be interested in...
Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet
The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.
Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.
Tocilizumab Shortage Prompts US FDA To Loosen CAR-T REMS Requirements
CAR-T cell immunotherapies can be administered when only one dose of Roche's Actemra is available on-site for each patient, rather than two doses required under REMS for the immunotherapies. The change is one of the few pandemic-related REMS revisions that has been made public.